How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy

被引：30

作者：

Fundytus, A. ^{[1
,2
]}

Booth, C. M. ^{[1
,2
,3
]}

Tannock, I. F. ^{[4
,5
]}

机构：

[1] Queens Univ, Canc Res Inst, Div Canc Care & Epidemiol, Kingston, ON, Canada

[2] Queens Univ, Dept Oncol, Kingston, ON, Canada

[3] Queens Univ, Dept Publ Hlth Sci, Kingston, ON, Canada

[4] Princess Margaret Canc Ctr, Div Med Oncol, Toronto, ON, Canada

[5] Univ Toronto, Toronto, ON, Canada

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷 / 07期

关键词：

PEMBROLIZUMAB; CHEMOTHERAPY; CARCINOMA; RECURRENT;

D O I：

10.1016/j.annonc.2021.03.208

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：833 / 836

页数：4

共 26 条

[1] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].

Balar, Arjun V. ;

Castellano, Daniel ;

O'Donnell, Peter H. ;

Grivas, Petros ;

Vuky, Jacqueline ;

Powles, Thomas ;

Plimack, Elizabeth R. ;

Hahn, Noah M. ;

de Wit, Ronald ;

Pang, Lei ;

Savage, Mary J. ;

Perini, Rodolfo F. ;

Keefe, Stephen M. ;

Bajorin, Dean ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2017, 18 (11) :1483-1492

[2] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J].

Burtness, Barbara ;

Harrington, Kevin J. ;

Greil, Richard ;

Soulieres, Denis ;

Tahara, Makoto ;

de Castro, Gilberto, Jr. ;

Psyrri, Amanda ;

Baste, Neus ;

Neupane, Prakash ;

Bratland, Ase ;

Fuereder, Thorsten ;

Hughes, Brett G. M. ;

Mesia, Ricard ;

Ngamphaiboon, Nuttapong ;

Rordorf, Tamara ;

Ishak, Wan Zamaniah Wan ;

Hong, Ruey-Long ;

Mendoza, Rene Gonzalez ;

Roy, Ananya ;

Zhang, Yayan ;

Gumuscu, Burak ;

Cheng, Jonathan D. ;

Jin, Fan ;

Rischin, Danny .

LANCET, 2019, 394 (10212) :1915-1928

[3] Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC [J].

Camidge, D. Ross ;

Doebele, Robert C. ;

Kerr, Keith M. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (06) :341-355

[4] PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas [J].

Cimino-Mathews, Ashley ;

Thompson, Elizabeth ;

Taube, Janis M. ;

Ye, Xiaobu ;

Lu, Yao ;

Meeker, Alan ;

Xu, Haiying ;

Sharma, Rajni ;

Lecksell, Kristen ;

Cornish, Toby C. ;

Cuka, Nathan ;

Argani, Pedram ;

Emens, Leisha A. .

HUMAN PATHOLOGY, 2016, 47 (01) :52-63

[5]

Cortes J, 2020, LANCET, V396, P1817, DOI 10.1016/S0140-6736(20)32531-9

[6] PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC) [J].

De Marchi, Pedro ;

Leal, Leticia Ferro ;

da Silva, Vinicius Duval ;

Albino da Silva, Eduardo Caetano ;

Cordeiro de Lima, Vladmir Claudio ;

Reis, Rui Manuel .

JOURNAL OF CLINICAL PATHOLOGY, 2021, 74 (11) :735-740

[7] Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC) [J].

de Ruiter, Emma J. ;

Mulder, Frans J. ;

Koomen, Bregje M. ;

Speel, Ernst-Jan ;

van den Hout, Mari F. C. M. ;

de Roest, Reinout H. ;

Bloemena, Elisabeth ;

Devriese, Lot A. ;

Willems, Stefan M. .

MODERN PATHOLOGY, 2021, 34 (06) :1125-1132

[8] PD-L1 assessment in urothelial carcinoma: a practical approach [J].

Eckstein, Markus ;

Cimadamore, Alessia ;

Hartmann, Arndt ;

Lopez-Beltran, Antonio ;

Cheng, Liang ;

Scarpelli, Marina ;

Montironi, Rodolfo ;

Gevaert, Thomas .

ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (22)

[9] Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study [J].

Emens, Leisha A. ;

Cruz, Cristina ;

Eder, Joseph Paul ;

Braiteh, Fadi ;

Chung, Cathie ;

Tolaney, Sara M. ;

Kuter, Irene ;

Nanda, Rita ;

Cassier, Philippe A. ;

Delord, Jean-Pierre ;

Gordon, Michael S. ;

ElGabry, Ehab ;

Chang, Ching-Wei ;

Sarkar, Indrani ;

Grossman, William ;

O'Hear, Carol ;

Fasso, Marcella ;

Molinero, Luciana ;

Schmid, Peter .

JAMA ONCOLOGY, 2019, 5 (01) :74-82

[10] Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors [J].

Guo, Hua ;

Ding, Qingqing ;

Gong, Yun ;

Gilcrease, Michael Z. ;

Zhao, Min ;

Zhao, Jun ;

Sui, Dawen ;

Wu, Yun ;

Chen, Hui ;

Liu, Hui ;

Zhang, Jinxia ;

Resetkova, Erika ;

Moulder, Stacy L. ;

Wang, Wei-Lien ;

Huo, Lei .

BREAST CANCER RESEARCH, 2020, 22 (01)

← 1 2 3 →